Sanofi has reported positive new data from a mid-stage study of its investigational anti-CD40L antibody in patients with relapsing multiple sclerosis (MS).

Results from the phase 2 study, being presented at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab significantly reduced disease activity in patients with relapsing forms of the disease.


This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by making a donation to pay for the server costs.